<DOC>
	<DOCNO>NCT02371434</DOCNO>
	<brief_summary>The aim trial collect evidence safety administer autologous CD4+CD25+FoxP3+ natural regulatory T cell ( nTregs ) living-donor renal transplant recipient . In addition , study determine whether post-transplant nTregs infusion allow taper conventional maintenance immunosuppression within 60 week transplantation .</brief_summary>
	<brief_title>The ONE Study nTreg Trial ( ONEnTreg13 )</brief_title>
	<detailed_description>The ONE Study aim explore feasibility , safety efficacy regulatory cell therapy adjunct immunosuppressive treatment context living-donor renal transplantation.The clinical trial present ( ONEnTreg13 ) test autologous , polyclonally expand CD4+CD25+FoxP3+ nTregs somatic cell-based medicinal product . The objective study determine whether administration nTregs recipient living-donor kidney transplant safe able polarize immunological response recipient away graft rejection towards graft acceptance , allow reduction dose pharmacological maintenance immunosuppression .</detailed_description>
	<criteria>Inclusion Criteria organ recipient : Chronic renal insufficiency GFR &lt; 15 ml/min , accept organ transplantation conference , register ET ( Euro Transplant ) positive vote live donor ethic commission ( Lebendspendekommission ) Berlin Medical Association . Willing able participate The ONE Study IM HEC Subprojects . Signed date write informed consent . For patient unable read and/or write , oral inform consent observe independent witness acceptable patient fully understood oral information give Investigator . The witness sign consent form behalf patient . Exclusion Criteria organ recipient : Patient previously receive tissue organ transplant plan kidney graft . Known contraindication protocolspecified treatment / medication . Genetically identical prospective organ donor HLA locus , call `` full house match '' ( 000 mismatch ) . PanelReactive Antibody ( PRA ) grade &gt; 40 % within last 6 month transplantation . Previous treatment desensitization procedure ( without IVIg ) . Concomitant malignancy history malignancy within 5 year study entry ( exclude successfullytreated nonmetastatic basal/squamous cell carcinoma skin ) . Evidence significant local systemic infection . CMVnegative recipient receive kidney CMVpositive donor . EBVnegative recipient receive kidney EBVpositive donor . HIVpositive suffering chronic viral hepatitis . Significant liver disease , define persistently elevate AST and/or ALT level &gt; 2 x ULN . Malignant premalignant hematological condition . Any uncontrolled medical condition concurrent disease could interfere study objective . Any condition , accord Investigator , would place subject undue risk . Ongoing treatment systemic immunosuppressive drug study entry . Participation another clinical trial study within 28 day prior plan study entry . Female patient childbearing potential positive pregnancy test enrolment . Female patient breastfeed . All female patient childbearing potential unless patient willing maintain highly effective method birth control duration study . Psychological , familial , sociological geographical factor potentially hamper compliance study protocol followup visit schedule . Any form drug alcohol abuse , psychiatric disorder , condition , opinion Investigator , may invalidate communication Investigator and/or designate study personnel . Patients unable freely give inform consent ( e.g . patient legal guardianship ) . Patients committed institution virtue order issue either judicial administrative authority Known allergy/hypersensitivity component study product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>